Why is Panacea Biotec falling/rising?

Short-Term Price Movement and Market Context

Panacea Biotec’s stock price demonstrated a strong intraday performance, reaching a high of ₹370, representing an 11.73% increase from previous levels. This surge came after a period of two consecutive days of falling prices, signalling a potential trend reversal. The stock traded within a wide range of ₹35, indicating heightened volatility and active trading interest. Despite this, the weighted average price suggests that a larger volume of shares exchanged hands closer to the lower end of the day’s price range, hinting at some selling pressure amid the rally.

From a technical perspective, the stock is currently trading above its 5-day and 20-day moving averages, which often signals short-term bullish momentum. However, it remains below its longer-term moving averages such as the 50-day, 100-day, and 200-day, reflecting that the broader trend may still be under pressure. Liquidity remains adequate for moderate trade sizes, with delivery volumes on 11 Dec falling by 23.66% compared to the five-day average, suggesting a slight dip in investor participation.

Institutional Interest Bolsters Confidence

One of the key drivers behind the recent price appreciation is the increasing participation of institutional investors. Over the previous quarter, these investors have raised their stake by 0.55%, now collectively holding 2.86% of Panacea Biotec. Institutional investors typically possess greater analytical resources and a longer-term investment horizon, which can lend credibility to the stock’s prospects despite recent challenges. Their increased involvement may have contributed to the positive sentiment and buying interest observed on 12-Dec.

Long-Term Fundamental Challenges Temper Optimism

Despite the recent price rally, Panacea Biotec’s long-term fundamentals remain weak. The company has experienced operating losses and poor growth over the past five years, with net sales declining at an annual rate of 0.13% and operating profit plummeting by 218.34%. This negative trajectory is further underscored by the company’s inability to service its debt effectively, reflected in an average EBIT to interest ratio of -9.36, signalling financial stress.

Recent quarterly results released in September 2025 were particularly disappointing, with profit before tax (excluding other income) falling sharply to a loss of ₹28.27 crores, a decline of 962.78%. Net losses after tax stood at ₹16.62 crores, down 907.2%, while cash and cash equivalents at half-year stood at a low ₹81.61 crores. These figures highlight ongoing operational difficulties and liquidity constraints that weigh heavily on the stock’s valuation and investor confidence.

Over the past year, Panacea Biotec’s stock has underperformed significantly, delivering a negative return of 22.03% compared to the Sensex’s positive 4.89%. This underperformance is compounded by a 79.9% decline in profits, indicating that the recent price rise is more of a short-term correction rather than a reflection of improved fundamentals.

Balancing Short-Term Gains Against Long-Term Risks

The recent surge in Panacea Biotec’s share price on 12-Dec can be attributed primarily to short-term technical factors and renewed institutional interest. The stock’s outperformance relative to its sector and the broader market on the day suggests that investors are responding to a potential bottoming out after a brief decline. However, the underlying financials paint a cautionary picture, with persistent operating losses, weak sales growth, and poor debt servicing capacity continuing to pose significant risks.

Investors should weigh the current price momentum against these fundamental challenges. While the stock’s three-year returns remain impressive at over 160%, this is overshadowed by the negative returns and deteriorating profitability over the last year. The mixed signals from technical indicators and institutional buying may offer short-term trading opportunities, but the company’s weak long-term outlook suggests prudence for those considering a sustained investment.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →